Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPI-11
- Development stage
- Preclinical
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Small Molecules
01
Overview
CPI-11 is a small molecule transcriptional inhibitor of CYP24A1, the primary enzyme responsible for the degradation of 1á,25-dihydroxyvitamin D3 (1,25D3). Identified through a high-throughput screen of the DIVERSet™ library by researchers at the Roswell Park Cancer Institute, CPI-11 was selected for its ability to inhibit 1,25D3-induced CYP24A1 promoter activity. By reducing the expression of CYP24A1, CPI-11 aims to prevent the rapid local inactivation of vitamin D in tumor environments, thereby potentially enhancing the anti-proliferative and pro-apoptotic effects of 1,25D3 in various cancers, including prostate, bladder, and kidney cancer.
Beyond the preview
Go deeper on CPI-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPI-11.